{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:41:05Z","timestamp":1781196065184,"version":"3.54.1"},"reference-count":120,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI1800943"],"award-info":[{"award-number":["PI1800943"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI19\/00254"],"award-info":[{"award-number":["FI19\/00254"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JRM"],"abstract":"<jats:p>Objective: To perform an economic evaluation on a multicomponent intervention programme for patients with fibromyalgia syndrome compared with usual clinical practice in primary care.\nDesign: A cost-utility analysis was conducted alongside a pragmatic randomised controlled trial (ClinicalTrials.gov: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04049006) from a societal perspective, a human capital approach, and a 1-year time horizon.\nPatients: Patients diagnosed with fibromyalgia\u00a0 syndrome from the public health system in south Catalonia, Spain.\nMethods: Crude and adjusted incremental cost- utility ratios were estimated to compare the treatment strategies based on cost estimations (direct medical costs and productivity losses) and quality-adjusted life years. One-way and 2-way deterministic sensitivity analyses were performed.\nResults: The final analysed sample comprised 297 individuals, 161 in the intervention group and 136 in the control group. A crude incremental cost-utility ratio of \u20ac 1,780.75 and an adjusted ratio of \u20ac 851.67 were obtained, indicating that the programme\u00a0 significantly improved patients\u2019 quality of life with a cost-increasing outcome that fell below the cost-effectiveness threshold. The sensitivity analysis\u00a0 confirmed these findings when\u00a0 varying large cost components, and showed dominance when increasing session attendance. \nConclusion: The proposed multicomponent intervention programme was cost-effective compared with usual care for fibromyalgia, which supports its addition to standard practice in the regional\u00a0 primary care service.<\/jats:p>","DOI":"10.2340\/jrm.v55.12361","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T09:08:51Z","timestamp":1702976931000},"page":"jrm12361","source":"Crossref","is-referenced-by-count":5,"title":["Cost-utility of a multicomponent intervention for fibromyalgia versus usual care: a pragmatic randomised controlled trial"],"prefix":"10.2340","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5935-6907","authenticated-orcid":false,"given":"Victoria Mailen","family":"Arfuch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-5726","authenticated-orcid":false,"given":"Carina","family":"Aguilar Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0889-2002","authenticated-orcid":false,"given":"Anna","family":"Berenguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5780-9888","authenticated-orcid":false,"given":"Rosa","family":"Caballol Angelats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3272-6861","authenticated-orcid":false,"given":"Alessandra Queiroga","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-7082","authenticated-orcid":false,"given":"No\u00e8lia","family":"Carrasco-Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5720-9049","authenticated-orcid":false,"given":"Gemma","family":"Gonz\u00e1lez Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9221-7028","authenticated-orcid":false,"given":"Maria Cinta","family":"Sancho Sol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1244-1108","authenticated-orcid":false,"given":"Immaculada","family":"Fust\u00e9 Anguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7874-4243","authenticated-orcid":false,"given":"Emilie","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4776-9162","authenticated-orcid":false,"given":"Emma","family":"Pettersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5653-996X","authenticated-orcid":false,"given":"Marc","family":"Casajuana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"44259","doi-asserted-by":"crossref","unstructured":"Giorgi V, Sirotti S, Romano ME, Marotto D, Ablin JN, Salaffi F, et al. Fibromyalgia: one year in review 2022. Clin Exp Rheumatol 2022; 40: 1065-1072.","DOI":"10.55563\/clinexprheumatol\/if9gk2"},{"key":"44260","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.55563\/clinexprheumatol\/if9gk2","DOI":"10.55563\/clinexprheumatol\/if9gk2"},{"key":"44261","doi-asserted-by":"crossref","unstructured":"Wolfe F, Walitt B, Perrot S, Rasker JJ, H\u00e4user W. Fibromyalgia diagnosis and biased assessment: sex, prevalence and bias. PLoS One 2018; 13: 1-14.","DOI":"10.1371\/journal.pone.0203755"},{"key":"44262","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0203755","DOI":"10.1371\/journal.pone.0203755"},{"key":"44263","doi-asserted-by":"crossref","unstructured":"Pasqual Marques A, Esp\u00edrito Santo A de S, Berssaneti AA, Matsutani LA, King Yuan SL. Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol 2017; 57: 356-363.","DOI":"10.1016\/j.rbre.2017.01.005"},{"key":"44264","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.rbr.2016.10.004","DOI":"10.1016\/j.rbr.2016.10.004"},{"key":"44265","unstructured":"Font Gay\u00e0 T, Bordoy Ferrer C, Juan Mas A, Seoane-Mato D, \u00c1lvarez Reyes F, Delgado S\u00e1nchez M, et al. Prevalence of fibromyalgia and associated factors in Spain. Clin Exp Rheumatol 2020; 38: 47-52."},{"key":"44266","doi-asserted-by":"crossref","unstructured":"Ursini F, Ciaffi J, Mancarella L, Lisi L, Brusi V, Cavallari C, et al. Fibromyalgia: a new facet of the post- COVID-19 syndrome spectrum? Results based survey from a web-based survey. RMD Open 2021; 7: e001735.","DOI":"10.1136\/rmdopen-2021-001735"},{"key":"44267","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001735","DOI":"10.1136\/rmdopen-2021-001735"},{"key":"44268","doi-asserted-by":"crossref","unstructured":"Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-172.","DOI":"10.1002\/art.1780330203"},{"key":"44269","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/art.1780330203","DOI":"10.1002\/art.1780330203"},{"key":"44270","doi-asserted-by":"crossref","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010; 62: 600-610.","DOI":"10.1002\/acr.20140"},{"key":"44271","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/acr.20140","DOI":"10.1002\/acr.20140"},{"key":"44272","doi-asserted-by":"crossref","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, H\u00e4user W, Katz RL, et al. 2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016; 46: 319-329.","DOI":"10.1016\/j.semarthrit.2016.08.012"},{"key":"44273","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.08.012","DOI":"10.1016\/j.semarthrit.2016.08.012"},{"key":"44274","doi-asserted-by":"crossref","unstructured":"de Tommaso M, Vecchio E, Nolano M. The puzzle of fibromyalgia between central sensitisation syndrome and small fiber neuropathy: a narrative review on neurophysiological and morphological evidence. Neurol Sci 2022; 43: 1667-1684.","DOI":"10.1007\/s10072-021-05806-x"},{"key":"44275","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10072-021-05806-x","DOI":"10.1007\/s10072-021-05806-x"},{"key":"44276","doi-asserted-by":"crossref","unstructured":"Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther 2009; 11: 117.","DOI":"10.1186\/ar2715"},{"key":"44277","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/ar2715","DOI":"10.1186\/ar2715"},{"key":"44278","doi-asserted-by":"crossref","unstructured":"Sicras-Mainar A, Rejas J, Navarro R, Milagrosa B, Morcillo A, Larios R, et al. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther 2009; 11: R54.","DOI":"10.1186\/ar2673"},{"key":"44279","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/ar2673","DOI":"10.1186\/ar2673"},{"key":"44280","unstructured":"Rivera J, Rejas J, Esteve-Vives J, Vallejo MA, Grupo ICAF. Resource utilisation and health care costs in patients diagnosed with fibromyalgia in Spain. Clin Exp Rheumatol 2009; 27: S39-S45."},{"key":"44281","doi-asserted-by":"crossref","unstructured":"Thompson JM, Luedtke CA, Oh TH, Shah ND, Long KH, King S, et al. Direct medical costs in patients with fibromyalgia: cost of illness and impact of a brief multidisciplinary treatment program. Am J Phys Med Rehabil 2011; 90: 40-46.","DOI":"10.1097\/PHM.0b013e3181fc7ff3"},{"key":"44282","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/PHM.0b013e3181fc7ff3","DOI":"10.1097\/PHM.0b013e3181fc7ff3"},{"key":"44283","unstructured":"Vervoort VM, Vriezekolk JE, Olde Hartman TC, Cats HA, van Helmond T, van der Laan WH, et al. Cost of illness and illness perceptions in patients with fibromyalgia. Clin Exp Rheumatol 2016; 34: S74-S82."},{"key":"44284","doi-asserted-by":"crossref","unstructured":"Cabo-Meseguer A, Cerda-Olmedo G, Trillo-Mata JL. Fibromyalgia: Prevalence, epidemiologic profiles and economic costs. Med Clin (Barc) 2017; 149: 441-448.","DOI":"10.1016\/j.medcle.2017.10.011"},{"key":"44285","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.medcli.2017.06.008","DOI":"10.1016\/j.medcli.2017.06.008"},{"key":"44286","doi-asserted-by":"crossref","unstructured":"Skaer TL. Fibromyalgia: disease synopsis, medication cost effectiveness and economic burden. Pharmacoeconomics 2014; 32: 457-466.","DOI":"10.1007\/s40273-014-0137-y"},{"key":"44287","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40273-014-0137-y","DOI":"10.1007\/s40273-014-0137-y"},{"key":"44288","doi-asserted-by":"crossref","unstructured":"Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, H\u00e4user W, FluB E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017; 76: 318-328.","DOI":"10.1136\/annrheumdis-2016-209724"},{"key":"44289","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/annrheumdis-2016-209724","DOI":"10.1136\/annrheumdis-2016-209724"},{"key":"44290","unstructured":"Yin JH, Peng GS, Ro LS. Multidisciplinary approach to Fibromyalgia: What are we learning from updated evidence-based medicine? Acta Neurol Taiwan 2022 Jan 18 [online ahead of print]."},{"key":"44291","doi-asserted-by":"crossref","unstructured":"Hernando-Garijo I, Jim\u00e9nez-Del-Barrio S, Mingo-G\u00f3mez T, Medrano-De-La-Fuente R, Ceballos-Laita L. Effectiveness of non-pharmacological conservative therapies in adults with fibromyalgia: a systematic review of high-quality clinical trials. J Back Musculoskelet Rehabil 2022; 35: 3-20.","DOI":"10.3233\/BMR-200282"},{"key":"44292","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3233\/BMR-200282","DOI":"10.3233\/BMR-200282"},{"key":"44293","doi-asserted-by":"crossref","unstructured":"Mascarenhas RO, Souza MB, Oliveira MX, Lacerda AC, Mendon\u00e7a VA, Henschke N, et al. Association of therapies with reduced pain and improved quality of life in patients with fibromyalgia: a systematic review and meta-analysis. JAMA Intern Med 2021; 181: 104-112. https:\/\/doi:10.1001\/jamainternmed.2020.5651","DOI":"10.1001\/jamainternmed.2020.5651"},{"key":"44294","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamainternmed.2020.5651","DOI":"10.1001\/jamainternmed.2020.5651"},{"key":"44295","doi-asserted-by":"crossref","unstructured":"Cabral CMN, Miyamoto GC, Franco KFM, Bosmans JE. Economic evaluations of educational, physical, and psychological treatments for fibromyalgia: a systematic review with meta-analysis. Pain 2021; 162: 2331-2345.","DOI":"10.1097\/j.pain.0000000000002233"},{"key":"44296","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/j.pain.0000000000002233","DOI":"10.1097\/j.pain.0000000000002233"},{"key":"44297","unstructured":"Mccabe C. What is cost-utility analysis? 2009. [Accessed 15 Jun 2022]. Available from http:\/\/www.bandolier.org.uk\/painres\/download\/whatis\/What_is_cost-util.pdf"},{"key":"44298","doi-asserted-by":"crossref","unstructured":"Luciano JV, Sabes-Figuera R, Cardenosa E, Pe\u00f1arrubia-Mar\u00eda MT, Fern\u00e1ndez-Vergel R, Garc\u00eda-Campayo J, et al. Cost-utility of a psychoeducational intervention in fibromyalgia patients compared with usual care: an economic evaluation alongside a 12-month randomised controlled trial. Clin J Pain 2013; 29: 702-711.","DOI":"10.1097\/AJP.0b013e318270f99a"},{"key":"44299","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/AJP.0b013e318270f99a","DOI":"10.1097\/AJP.0b013e318270f99a"},{"key":"44300","doi-asserted-by":"crossref","unstructured":"Luciano JV, D'Amico F, Cerd\u00e0-Lafont M, Pe\u00f1arrubia-Mar\u00eda MT, Knapp M, Cuesta-Vargas AI, et al. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomised controlled trial. Arthritis Res Ther 2014; 16: 1-17.","DOI":"10.1186\/s13075-014-0451-y"},{"key":"44301","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13075-014-0451-y","DOI":"10.1186\/s13075-014-0451-y"},{"key":"44302","doi-asserted-by":"crossref","unstructured":"Feliu-Soler A, Borr\u00e0s X, Pe\u00f1arrubia-Mar\u00eda MT, Pe\u00f1arrubia-Mar\u00eda MT, Knapp M, Cuesta-Vargas AI, et al. Cost-utility and biological underpinnings of Mindfulness-Based Stress Reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study). BMC Complement Altern Med 2016; 16: 1-16.","DOI":"10.1186\/s12906-016-1068-2"},{"key":"44303","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12906-016-1068-2","DOI":"10.1186\/s12906-016-1068-2"},{"key":"44304","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Aranda A, D'Amico F, Feliu-Soler A, McCracken LM, Pe\u00f1arrubia-Mar\u00eda MT, Andr\u00e9s-Rodr\u00edguez L, et al. Cost-utility of mindfulness-based stress reduction for fibromyalgia versus a multicomponent intervention and usual care: a 12-month randomized controlled trial (EUDAIMON Study). J Clin Med 2019; 8: 1068.","DOI":"10.3390\/jcm8071068"},{"key":"44305","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jcm8071068","DOI":"10.3390\/jcm8071068"},{"key":"44306","doi-asserted-by":"crossref","unstructured":"Luciano J V, D'Amico F, Feliu-Soler A, McCracken LM, Aguado J, Pe\u00f1arrubia-Mar\u00eda MT, et al. Cost-utility of group acceptance and commitment therapy for fibromyalgia versus recommended drugs: an economic analysis alongside a 6-month randomized controlled trial conducted in Spain (EFFIGACT Study). J Pain 2017; 18: 868-880.","DOI":"10.1016\/j.jpain.2017.03.001"},{"key":"44307","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jpain.2017.03.001","DOI":"10.1016\/j.jpain.2017.03.001"},{"key":"44308","doi-asserted-by":"crossref","unstructured":"D'amico F, Feliu-Soler A, Montero-Mar\u00edn J, Pe\u00f1arrub\u00eda-Mar\u00eda MT, Navarro-Gil M, Van Gordon W, et al. Cost-utility of attachment-based compassion therapy (ABCT) for fibromyalgia compared to relaxation: a pilot randomised controlled trial. J Clin Med 2020; 9: 726.","DOI":"10.3390\/jcm9030726"},{"key":"44309","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jcm9030726","DOI":"10.3390\/jcm9030726"},{"key":"44310","doi-asserted-by":"crossref","unstructured":"Caballol Angelats R, Gon\u00e7alves AQ, Aguilar Mart\u00edn C, Sol MCS, Serra GG, Casajuana M, et al. Effectiveness, cost-utility, and benefits of a multicomponent therapy to improve the quality of life of patients with fibromyalgia in primary care: a mixed methods study protocol. Med (United States) 2019; 98: e17289.","DOI":"10.1097\/MD.0000000000017289"},{"key":"44311","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/MD.0000000000017289","DOI":"10.1097\/MD.0000000000017289"},{"key":"44312","doi-asserted-by":"crossref","unstructured":"J\u00f6nsson B. Editorial: ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Heal Econ 2009; 10: 357-359.","DOI":"10.1007\/s10198-009-0173-2"},{"key":"44313","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10198-009-0173-2","DOI":"10.1007\/s10198-009-0173-2"},{"key":"44314","doi-asserted-by":"crossref","unstructured":"DOI: 10.1007\/s10198-009-0173-2","DOI":"10.1007\/s10198-009-0173-2"},{"key":"44315","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10198-009-0173-2","DOI":"10.1007\/s10198-009-0173-2"},{"key":"44316","unstructured":"Kobelt G. Health Economics: an Introduction to Economic Evaluation. Vol 314. Third Edit. (Office of Health Economics (OHE), ed.). OHE Monograph 2013."},{"key":"44317","doi-asserted-by":"crossref","unstructured":"Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B. Improving the reporting of pragmatic trials : an ex-tension of the CONSORT statement. BMJ 2008; 337: a2390.","DOI":"10.1136\/bmj.a2390"},{"key":"44318","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.a2390","DOI":"10.1136\/bmj.a2390"},{"key":"44319","doi-asserted-by":"crossref","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations. Value Heal 2022; 25: 3-9.","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"44320","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"44321","doi-asserted-by":"crossref","unstructured":"Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. Int J Nurs Stud 2013; 50: 587-592.","DOI":"10.1016\/j.ijnurstu.2012.09.010"},{"key":"44322","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijnurstu.2012.09.010","DOI":"10.1016\/j.ijnurstu.2012.09.010"},{"key":"44323","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Feijo\u00f3 S, Rodr\u00edguez-Caro A. [Pharmaceutical copayment in Spain after the 2012 reform from the user's perspective. Evidence of inequity?] Gac Sanit 2021; 35: 138-144 (in Spanish).","DOI":"10.1016\/j.gaceta.2019.09.009"},{"key":"44324","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.gaceta.2019.09.009","DOI":"10.1016\/j.gaceta.2019.09.009"},{"key":"44325","unstructured":"Celaya M, Ib\u00e1\u00f1ez D, Laseca N, L\u00f3pez A, Romero C, Valls E. Guia per a l'avaluaci\u00f3 de la fibromi\u00e0lgia i de la s\u00edndrome de fatiga cr\u00f2nica. Barcelona: Direcci\u00f3 General d'Ordenaci\u00f3 Professional i Regulaci\u00f3 Sanit\u00e0ria; 2017. [accessed 2022 Jun 17]. Available from: http:\/\/hdl.handle.net\/11351\/5652"},{"key":"44326","unstructured":"Catalunya G de. Diari Oficial de la Generalitat de Catalunya. [accessed 2022 Mar 15]. Available from: https:\/\/dogc.gencat.cat\/es"},{"key":"44327","unstructured":"World Health Organization (WHO). ICD-10: International Statistical Classification of Diseases and Related Health Problems: tenth revision. 2nd edn. Geneva: World Health Organization; 2004."},{"key":"44328","doi-asserted-by":"crossref","unstructured":"Efron B. Forcing a Sequential Experiment to be balanced. Biometrika 1971; 58: 403-417.","DOI":"10.1093\/biomet\/58.3.403"},{"key":"44329","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/biomet\/58.3.403","DOI":"10.1093\/biomet\/58.3.403"},{"key":"44330","unstructured":"Alonso J. Versi\u00f3n espa\u00f1ola de SF-36v2TM Health Survey \u00a9 1996, 2000 adaptada por J. Alonso y cols 2003. Heal Surv Published online 2003: 1-8. [accessed 2020 Jan 10]. Available from: http:\/\/www.ser.es\/wp-content\/uploads\/2015\/03\/SF36_CUESTIONARIOpdf.pdf"},{"key":"44331","doi-asserted-by":"crossref","unstructured":"Rebollo P, Mor\u00eds J, Ortega T, Vald\u00e9s C, Ortega F. Estimating utility values for health status using the Spanish version of the SF-36. Validity of the SF-6D index vs EQ-5D. Med Clin (Barc) 2007; 128: 536-537.","DOI":"10.1157\/13101163"},{"key":"44332","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1157\/13101163","DOI":"10.1157\/13101163"},{"key":"44333","unstructured":"Abell\u00e1n-Perpi\u00f1\u00e1n JM. Utilidades SF-6D Para Espa\u00f1a. Gu\u00eda de Uso. Gu\u00eda de uso 2012\/8. C\u00e1tedra de Econom\u00eda de la Salud. Universidad Pablo de Olavide. Sevilla: Consejer\u00eda de Salud de la Junta de Andaluc\u00eda; 2013."},{"key":"44334","unstructured":"Gisbert, R and Brosa M. Spanish health costs and cost-effectiveness ratios Database: eSalud Published 2007 [accessed 2022 Jun 30]. Available from: http:\/\/www.oblikue.com\/bddcostes\/"},{"key":"44335","unstructured":"Ministerio de Sanidad de Espa\u00f1a. Bolet\u00edn Oficial Del Estado Orden SND\/1121\/2020.; 2020 [accessed 2022 Jun 30]. Available from: https:\/\/www.boe.es\/boe\/dias\/2020\/11\/28\/pdfs\/BOE-A-2020-15176.pdf"},{"key":"44336","unstructured":"Instituto Nacional de Estad\u00edstica.Coste laboral por trabajador, comunidad aut\u00f3noma, sectores de actividad [Labor wages per worker, autonomous community, sectors of activity][accessed Nov 15, 2021]. Available from https:\/\/www.ine.es\/jaxiT3\/Tabla.htm?t=60611"},{"key":"44337","unstructured":"Gobierno de Espa\u00f1a. Real Decreto 8\/2015 por el que e aprueba el texto refundido de la Ley General de la Seguridad Social [Royal Decree 8\/2015 approving the consolidated text of the General Social Security Law]. Bolet\u00edn del Estado. Published online2015: 1-157 [accessed 2022 Mar 25]. Available from: http:\/\/www.boe.es\/boe\/dias\/1994\/06\/29\/pdfs\/A20658-20708.pdf."},{"key":"44338","unstructured":"Seguridad Social Espa\u00f1a. Prestaci\u00f3n de Incapacidad Temporal [Temporary disability benefits] [accessed 2022 Jun 30]. Available from: https:\/\/www.seg-social.es\/wps\/portal\/wss\/internet\/InformacionUtil\/44539\/44667#:~:text=En general%2C el pago lo,INSS o de la mutua."},{"key":"44339","unstructured":"RStudio Team. RStudio: Integrated development environment for R. Published online 2022. Available from: http:\/\/www.rstudio.com\/"},{"key":"44340","doi-asserted-by":"crossref","unstructured":"Mantopoulos T, Mitchell PM, Welton NJ, McManus R, Andronis L. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results. Eur J Heal Econ 2016; 17: 927-938.","DOI":"10.1007\/s10198-015-0731-8"},{"key":"44341","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10198-015-0731-8","DOI":"10.1007\/s10198-015-0731-8"},{"key":"44342","doi-asserted-by":"crossref","unstructured":"Cohen DJ, Reynolds MR. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol 2008; 52: 2119-2126.","DOI":"10.1016\/j.jacc.2008.09.018"},{"key":"44343","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jacc.2008.09.018","DOI":"10.1016\/j.jacc.2008.09.018"},{"key":"44344","doi-asserted-by":"crossref","unstructured":"Andronis L, Barton P, Bryan S. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technol Assess 2009; 13: iii, ix-xi, 1-61.","DOI":"10.3310\/hta13290"},{"key":"44345","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3310\/hta13290","DOI":"10.3310\/hta13290"},{"key":"44346","doi-asserted-by":"crossref","unstructured":"Thabane L, Mbuagbaw L, Zhang S, Samaan Z, Marcucci M, Ye C, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol 2013; 13: 92.","DOI":"10.1186\/1471-2288-13-92"},{"key":"44347","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1471-2288-13-92","DOI":"10.1186\/1471-2288-13-92"},{"key":"44348","doi-asserted-by":"crossref","unstructured":"Arfuch VM, Aguilar Mart\u00edn C, Berenguera A, Caballol Angelats R, Carrasco-Querol N, Serra GG, et al. Cost-utility analysis of a multicomponent intervention for fibromyalgia syndrome in primary care versus usual clinical practice: study protocol for an economic evaluation of a randomised control trial. BMJ Open 2021; 11: e043562.","DOI":"10.1136\/bmjopen-2020-043562"},{"key":"44349","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjopen-2020-043562","DOI":"10.1136\/bmjopen-2020-043562"},{"key":"44350","doi-asserted-by":"crossref","unstructured":"Vallejo MA, Rivera J, Esteve-Vives J, Rodr\u00edguez-Mu\u00f1oz MF. [Use of the Hospital Anxiety and Depression Scale (HADS) to evaluate anxiety and depression in fibromyalgia patients]. Rev Psiquiatr Salud Ment 2012; 5: 107-114 (in Spanish).","DOI":"10.1016\/j.rpsmen.2012.01.004"},{"key":"44351","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.rpsmen.2012.01.004","DOI":"10.1016\/j.rpsmen.2012.01.004"},{"key":"44352","doi-asserted-by":"crossref","unstructured":"Cabrera V, Mart\u00edn-Arag\u00f3n M, Terol MC, Nu\u00f1ez R, Pastor MA. Hospital Anxiety and depression Scale (HADS) in fibromyalgia: sensitivity and specific analysis. Ter Psicol\u00f3gica 2015; 33: 181-193.","DOI":"10.4067\/S0718-48082015000300003"},{"key":"44353","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4067\/S0718-48082015000300003","DOI":"10.4067\/S0718-48082015000300003"},{"key":"44354","doi-asserted-by":"crossref","unstructured":"Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 2009; 11: R120.","DOI":"10.1186\/ar2783"},{"key":"44355","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/ar2783","DOI":"10.1186\/ar2783"},{"key":"44356","doi-asserted-by":"crossref","unstructured":"Salgueiro M, Garc\u00eda-Leiva JM, Ballesteros J, Hidalgo J, Molina R, Calandre EP. Validation of a Spanish version of the Revised Fibromyalgia Impact Questionnaire (FIQR). Health Qual Life Outcomes 2013; 11: 1-8.","DOI":"10.1186\/1477-7525-11-132"},{"key":"44357","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1477-7525-11-132","DOI":"10.1186\/1477-7525-11-132"},{"key":"44358","unstructured":"Valls Llobet C. [Differential diagnosis of pain and fibromyalgia]. Anu Psicol Univ Barcelona 2008; 39: 87-92 (in Spanish)."},{"key":"44359","doi-asserted-by":"crossref","unstructured":"Vallejo-Torres L, Garc\u00eda-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ 2018; 27: 746-761.","DOI":"10.1002\/hec.3633"},{"key":"44360","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/hec.3633","DOI":"10.1002\/hec.3633"},{"key":"44361","doi-asserted-by":"crossref","unstructured":"Paulden M. Why it's time to abandon the ICER. Pharmacoeconomics 2020; 38: 781-784.","DOI":"10.1007\/s40273-020-00915-5"},{"key":"44362","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40273-020-00915-5","DOI":"10.1007\/s40273-020-00915-5"},{"key":"44363","doi-asserted-by":"crossref","unstructured":"Paulden M. Calculating and interpreting ICERs and net benefit. Pharmacoeconomics 2020; 38: 785-807.","DOI":"10.1007\/s40273-020-00914-6"},{"key":"44364","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40273-020-00914-6","DOI":"10.1007\/s40273-020-00914-6"},{"key":"44365","doi-asserted-by":"crossref","unstructured":"L\u00f3pez Bastida J, Oliva J, Anto\u00f1anzas F, Garc\u00eda-Alt\u00e9s A, Gisbert R, Mar J, et al. [A proposed guideline for economic evaluation of health technologies]. Gac Sanit 2009; 24: 154-170 (in Spanish).","DOI":"10.1016\/j.gaceta.2009.07.011"},{"key":"44366","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.gaceta.2009.07.011","DOI":"10.1016\/j.gaceta.2009.07.011"},{"key":"44367","unstructured":"NICE. NICE Health Technology Evaluations: the manual (PMG36) 2022 [accessed 2022 Jul 2]. Available from: https:\/\/www.nice.org.uk\/process\/pmg36"},{"key":"44368","doi-asserted-by":"crossref","unstructured":"Cavalli G, Cariddi A, Ferrari J, Suzzi B, Tomelleri A, Campochiaro C, et al. Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. Rheumatol 2021; 60: 465-467.","DOI":"10.1093\/rheumatology\/keaa738"},{"key":"44369","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa738","DOI":"10.1093\/rheumatology\/keaa738"},{"key":"44370","unstructured":"Schweiger V, Secchettin E, Perini G, Martini A, Donadello K, Gottin L, et al. Quality of life and psychological assessment in patients with fibromyalgia syndrome during COVID-19 pandemic in Italy : prospective observational study. Signa Vitae 2022; 18: 41-46."},{"key":"44371","doi-asserted-by":"crossref","unstructured":"Colas C, Jumel A, Vericel M, Barth N. Understanding experiences of fibromyalgia patients involved in the Fimouv study during COVID-19 lockdown Front Psuchol 2021; 12: 1-9.","DOI":"10.3389\/fpsyg.2021.645092"},{"key":"44372","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fpsyg.2021.645092","DOI":"10.3389\/fpsyg.2021.645092"},{"key":"44373","doi-asserted-by":"crossref","unstructured":"Carrillo-de-la-Pe\u00f1a MT, Gonz\u00e1lez-Villar A, Tri\u00f1anes Y. Effects of the COVID-19 pandemic on chronic pain in Spain : a scoping review. PAIN reports 2021; 6: e899.","DOI":"10.1097\/PR9.0000000000000899"},{"key":"44374","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/PR9.0000000000000899","DOI":"10.1097\/PR9.0000000000000899"},{"key":"44375","doi-asserted-by":"crossref","unstructured":"Arfuch VM, Gon\u00e7alves AQ, Caballol Angelats R, Mart\u00edn CA, Carrasco-Querol N, Sol MCS, et al. Patients' appraisals about a multicomponent intervention for fibromyalgia syndrome in primary care: a focus group study. Int J Qual Stud Health Well-being 2021; 16: 2005760.","DOI":"10.1080\/17482631.2021.2005760"},{"key":"44376","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/17482631.2021.2005760","DOI":"10.1080\/17482631.2021.2005760"},{"key":"44377","doi-asserted-by":"crossref","unstructured":"O'Sullivan AK, Thompson D, Drummond MF. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? Value Health 2005; 8: 67-79.","DOI":"10.1111\/j.1524-4733.2005.03065.x"},{"key":"44378","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1524-4733.2005.03065.x","DOI":"10.1111\/j.1524-4733.2005.03065.x"}],"container-title":["Journal of Rehabilitation Medicine"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/jrm\/article\/download\/12361\/40232","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/jrm\/article\/download\/12361\/40232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T09:09:51Z","timestamp":1702976991000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/jrm\/article\/view\/12361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":120,"URL":"https:\/\/doi.org\/10.2340\/jrm.v55.12361","relation":{},"ISSN":["1651-2081"],"issn-type":[{"value":"1651-2081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]}}}